annual CFF:
$445.85M+$92.53M(+26.19%)Summary
- As of today (September 16, 2025), AKRO annual cash flow from financing activities is $445.85 million, with the most recent change of +$92.53 million (+26.19%) on December 31, 2024.
- During the last 3 years, AKRO annual CFF has risen by +$445.24 million (+73960.80%).
- AKRO annual CFF is now at all-time high.
Performance
AKRO Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$3.43M-$392.10M(-99.13%)Summary
- As of today (September 16, 2025), AKRO quarterly cash flow from financing activities is $3.43 million, with the most recent change of -$392.10 million (-99.13%) on June 30, 2025.
- Over the past year, AKRO quarterly CFF has increased by +$3.58 million (+2388.67%).
- AKRO quarterly CFF is now -99.13% below its all-time high of $395.53 million, reached on March 31, 2025.
Performance
AKRO quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$478.02M+$3.58M(+0.76%)Summary
- As of today (September 16, 2025), AKRO TTM cash flow from financing activities is $478.02 million, with the most recent change of +$3.58 million (+0.76%) on June 30, 2025.
- Over the past year, AKRO TTM CFF has increased by +$109.93 million (+29.86%).
- AKRO TTM CFF is now -32.21% below its all-time high of $705.10 million, reached on March 31, 2024.
Performance
AKRO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AKRO Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +26.2% | +2388.7% | +29.9% |
| 3 y3 years | +10000.0% | -90.2% | +1253.4% |
| 5 y5 years | +364.5% | +3333.0% | +10000.0% |
AKRO Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -99.1% | +2388.7% | -32.2% | +1253.4% |
| 5 y | 5-year | at high | >+9999.0% | -99.1% | +2388.7% | -32.2% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -99.1% | +313.6% | -32.2% | >+9999.0% |
AKRO Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $3.43M(-99.1%) | $478.02M(+0.8%) |
| Mar 2025 | - | $395.53M(+420.5%) | $474.44M(+6.4%) |
| Dec 2024 | $445.85M(+26.2%) | $75.99M(+2377.7%) | $445.85M(+20.4%) |
| Sep 2024 | - | $3.07M(-2144.7%) | $370.36M(+0.6%) |
| Jun 2024 | - | -$150.00K(-100.0%) | $368.10M(-47.8%) |
| Mar 2024 | - | $366.94M(>+9900.0%) | $705.10M(+99.6%) |
| Dec 2023 | $353.32M(+38.2%) | $502.00K(-37.7%) | $353.32M(-0.6%) |
| Sep 2023 | - | $806.00K(-99.8%) | $355.54M(-37.9%) |
| Jun 2023 | - | $336.86M(+2123.0%) | $572.63M(+111.6%) |
| Mar 2023 | - | $15.15M(+456.5%) | $270.65M(+5.9%) |
| Dec 2022 | $255.63M(>+9900.0%) | $2.72M(-98.8%) | $255.63M(+1.0%) |
| Sep 2022 | - | $217.90M(+524.8%) | $253.15M(+616.7%) |
| Jun 2022 | - | $34.88M(>+9900.0%) | $35.32M(+4874.8%) |
| Mar 2022 | - | $132.00K(-45.7%) | $710.00K(+17.9%) |
| Dec 2021 | $602.00K | $243.00K(+252.2%) | $602.00K(+44.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $69.00K(-74.1%) | $418.00K(-99.8%) |
| Jun 2021 | - | $266.00K(+1008.3%) | $203.13M(+0.1%) |
| Mar 2021 | - | $24.00K(-59.3%) | $202.97M(-0.1%) |
| Dec 2020 | $203.11M(+111.6%) | $59.00K(-100.0%) | $203.11M(-0.0%) |
| Sep 2020 | - | $202.78M(>+9900.0%) | $203.16M(<-9900.0%) |
| Jun 2020 | - | $100.00K(-39.0%) | -$1.23M(-101.3%) |
| Mar 2020 | - | $164.00K(+42.6%) | $96.87M(+0.9%) |
| Dec 2019 | $95.99M(+12.9%) | $115.00K(-107.2%) | $95.99M(-42.2%) |
| Sep 2019 | - | -$1.61M(-101.6%) | $166.10M(-1.0%) |
| Jun 2019 | - | $98.20M(<-9900.0%) | $167.70M(+99.0%) |
| Mar 2019 | - | -$720.00K(-101.0%) | $84.29M(-0.8%) |
| Dec 2018 | $85.01M(+1600.1%) | $70.22M(>+9900.0%) | $85.01M(+475.0%) |
| Sep 2018 | - | $0.00(-100.0%) | $14.78M(0.0%) |
| Jun 2018 | - | $14.78M(>+9900.0%) | $14.78M(>+9900.0%) |
| Mar 2018 | - | $0.00 | $0.00 |
| Dec 2017 | $5.00M | - | - |
FAQ
- What is Akero Therapeutics, Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Akero Therapeutics, Inc.?
- What is Akero Therapeutics, Inc. annual CFF year-on-year change?
- What is Akero Therapeutics, Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Akero Therapeutics, Inc.?
- What is Akero Therapeutics, Inc. quarterly CFF year-on-year change?
- What is Akero Therapeutics, Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Akero Therapeutics, Inc.?
- What is Akero Therapeutics, Inc. TTM CFF year-on-year change?
What is Akero Therapeutics, Inc. annual cash flow from financing activities?
The current annual CFF of AKRO is $445.85M
What is the all time high annual CFF for Akero Therapeutics, Inc.?
Akero Therapeutics, Inc. all-time high annual cash flow from financing activities is $445.85M
What is Akero Therapeutics, Inc. annual CFF year-on-year change?
Over the past year, AKRO annual cash flow from financing activities has changed by +$92.53M (+26.19%)
What is Akero Therapeutics, Inc. quarterly cash flow from financing activities?
The current quarterly CFF of AKRO is $3.43M
What is the all time high quarterly CFF for Akero Therapeutics, Inc.?
Akero Therapeutics, Inc. all-time high quarterly cash flow from financing activities is $395.53M
What is Akero Therapeutics, Inc. quarterly CFF year-on-year change?
Over the past year, AKRO quarterly cash flow from financing activities has changed by +$3.58M (+2388.67%)
What is Akero Therapeutics, Inc. TTM cash flow from financing activities?
The current TTM CFF of AKRO is $478.02M
What is the all time high TTM CFF for Akero Therapeutics, Inc.?
Akero Therapeutics, Inc. all-time high TTM cash flow from financing activities is $705.10M
What is Akero Therapeutics, Inc. TTM CFF year-on-year change?
Over the past year, AKRO TTM cash flow from financing activities has changed by +$109.93M (+29.86%)